RESUMEN
Major depressive disorder (MDD) is a prevalent psychiatric disorder associated with brain inflammation and neuronal damage. Derived from the Aesculus chinensis Bunge fruit, escin has shown anti-inflammatory and neuroprotective effects. However, its potential as a treatment for MDD is unclear. This study investigates the antidepressant properties of escin using in vivo experimentation. The chronic unpredictable mild stress (CUMS) model was used to analyze the potential antidepressant effects and underlying mechanisms of escin. Wistar rats were exposed to CUMS for 35 consecutive days to induce MDD. The rats were then given either escin (1, 3, and 10 mg/kg) or fluoxetine (2 mg/kg) on a daily basis. Notably, escin significantly alleviated the depressive behaviors induced by CUMS, as evaluated through a series of behavioral assessments. Moreover, escin administration reduced TNF-α, IL-1ß, and IL-6 levels in the hippocampus. It also decreased serum adrenal cortical hormone (ACTH) and corticosterone (CORT) levels while increasing 5-HT and Brain-derived neurotrophic factor (BDNF) levels in the CUMS rats, as measured by the enzyme-linked immunosorbent assay (ELISA). Pathological changes in the hippocampal regions were identified through Nissl staining, and Western blotting was used to quantify the protein levels of BDNF, TrkB, CREB, TLR4, MyD88, and NF-κB. Escin mitigated neuronal injury, elevated TrkB, BDNF, and CREB, and reduced TLR4, MyD88, and NF-κB protein levels in CUMS rats. The data from this study suggest that escin holds the potential for alleviating depression-like symptoms induced by CUMS. This effect may be mediated through the modulation of two signaling pathways, BDNF/TrkB/CREB and TLR4/MyD88/NF-κB.
RESUMEN
The application of an inhibitor to the remaining coal in the goaf not only prevents spontaneous combustion of the coal seam in the mining area but also greatly enhances the capacity of coal to adsorb CO2. To investigate the mechanism by which inhibitors improve the CO2 adsorption capacity of the coal seam in the goaf, we conducted swelling experiments, infrared spectroscopy, scanning electron microscopy, and X-ray diffraction analyses to examine the microstructural changes in the adsorption of CO2 before and after inhibition. The results indicate that after inhibition, the number of hydrogen bonds between coal macromolecules decreased, and the samples exhibited approximately 5% swelling. This swelling of the coal macromolecular structure and the increased distance between coal particles create additional space for CO2 sequestration, which is a critical factor contributing to the enhanced CO2 adsorption capacity of coal. The mineral composition of coal consists of 75.6% kaolinite, and inhibition leads to a reduction in kaolinite content by 0.8-7.9%. After inhibition, the swelling and disintegration of kaolinite cause uneven stress, resulting in changes to the pore structure. Closed pores filled with kaolinite transform into open pores, and the original pores crack, forming new pores and pore channels. The dissolution of kaolinite particles increases the porosity of the coal, further facilitating gas adsorption. Among the three inhibitors tested, the most effective in enhancing CO2 sequestration by bituminous coal in the mining area was the urea solution. This study holds significant importance in improving the CO2 sequestration capacity of residual coal in goaves.
RESUMEN
Scutellarin is used to treat brain ischaemia. However, its underlying mechanism of action remains unclear. This study aimed to elucidate the potential mechanism of action of scutellarin in brain ischaemia through network pharmacology and experimental verification. The JAK2/STAT3 signalling pathway was identified and experimentally verified. Expression of JAK2/STAT3 signalling related proteins in TNC-1 astrocytes with BV-2 microglia-conditioned medium (CM), CM + lipopolysaccharide (LPS) (CM + L), and CM pretreated with scutellarin + LPS (CM + SL) was analysed by Western Blot and immunofluorescence staining. Expression levels of JAK2, p-JAK2, STAT3, and p-STAT3 were evaluated in astrocytes pre-treated with AG490. Middle cerebral artery occlusion (MCAO) in rats was performed in different experimental groups to detect expression of the above biomarkers. Network pharmacology suggested that the JAK2/STAT3 signalling pathway is one of the mechanisms by which scutellarin mitigates cerebral ischaemic damage. In TNC-1 astrocytes, p-JAK2 and p-STAT3 expression were significantly up-regulated in the CM + L group. Scutellarin promoted the up-regulation of various markers and AG490 neutralised the effect of scutellarin. In vivo, up-regulation of p-JAK2 and p-STAT3 after ischaemia is known. These results are consistent with previous reports. Scutellarin further enhanced this upregulation at 1, 3, and 7 d after MCAO. Scutellarin exerts its therapeutic effects on cerebral ischaemia by activating the astrocyte JAK2/STAT3 signalling, which provides a firm experimental basis for its clinical application.
Asunto(s)
Lesiones Encefálicas , Isquemia Encefálica , Animales , Ratas , Farmacología en Red , Lipopolisacáridos , Isquemia Encefálica/tratamiento farmacológico , Medios de Cultivo Condicionados , Janus Quinasa 2RESUMEN
Scutellarin, an herbal agent, is known to possess anti-oxidant and anti-inflammatory properties. In activated microglia, it has been reported that this is achieved through acting on the MAPKs, a key pathway that regulates microglia activation. This study sought to determine if scutellarin would affect the commonly described microglia phenotypes, namely, M1 and M2, thought to contribute to pro- and anti-inflammatory roles, respectively. This is in consideration of its potential effect on the polarization of microglia phenotypes that are featured prominently in cerebral ischemia. For this purpose, we have used an experimentally induced cerebral ischemia rat model and LPS-stimulated BV-2 cell model. Thus, by Western blot and immunofluorescence, we show here a noticeable increase in expression of M2 microglia markers, namely, CD206, Arg1, YM1/2, IL-4 and IL-10 in activated microglia both in vivo and in vitro. Besides, we have confirmed that Scutellarin upregulated expression of Arg1, IL-10 and IL-4 in medium supernatants of BV-2 microglia. Remarkably, scutellarin treatment markedly augmented the increased expression of the respective markers in activated microglia. It is therefore suggested scutellarin can exert the polarization of activated microglia from M1 to M2 phenotype. Because M1 microglia are commonly known to be proinflammatory, while M2 microglia are anti-inflammatory and neuroprotective effect, it stands to reason therefore that with the increase of M2 microglia which became predominant by scutellarin, the local inflammatory response is ameliorated. More importantly, we have found that scutellarin promotes the M2 polarization through inhibiting the JNK and p38 signaling pathways, and concomitantly augmenting the ERK1/2 signaling pathway. This lends its strong support from observations in LPS activated BV-2 microglia treated with p38 and JNK inhibitors in which expression of M2 markers was increased; on the other hand, in cells subjected to ERK1/2 inhibitor treatment, the expression was suppressed. In light of the above, MAPKs pathway is deemed to be a potential therapeutic target of scutellarin in mitigating microglia mediated neuroinflammation in activated microglia.
Asunto(s)
Isquemia Encefálica , Microglía , Ratas , Animales , Microglía/metabolismo , Interleucina-10/metabolismo , Lipopolisacáridos/farmacología , Interleucina-4 , Antiinflamatorios/farmacología , Isquemia Encefálica/metabolismoRESUMEN
Jinwujiangu capsule (JWJGC) is a traditional Chinese medicine formula used to treat rheumatoid arthritis (RA). However, whether its mechanism is associated with pyroptosis remains unclear. In this study, the ability of JWJGC to inhibit the growth of fibroblast-like synoviocytes of RA (RA-FLS) through pyroptosis was evaluated. The cells isolated from patients with RA were identified by hematoxylin and eosin (H&E) staining, immunohistochemistry, and flow cytometry. After RA-FLS were treated with different concentrations of JWJGC-containing serum, the cell proliferation inhibition rate, expression of caspase-1/3/4/5, NOD-like receptor protein 3 (NLRP3), gasdermin-D (GSDMD), and apoptosis-associated speck-like protein containing a CARD (ASC), concentrations of interleukin-1ß (IL-1ß) and interleukin-18 (IL-18), the activity of lactic dehydrogenase (LDH), and pyroptosis were evaluated. The results showed that JWJGC increased the proliferative inhibition rate, decreased the expression of caspase-1/3/4/5, GSDMD, NLRP3, and ASC, suppressed the expression of IL-1ß and IL-18, induced the activity of LDH, and downregulated the number of double-positive FITC anti-caspase-1 and PI. Generally, our findings suggest that JWJGC can regulate NLRP3/CAPSES/GSDMD in treating RA-FLS through pyroptosis.
RESUMEN
BACKGROUND: Gastrodin (GAS) has been proven to play a therapeutic role in a variety of neurological diseases by affecting activated astrocytes, however, the underlying mechanisms have not been fully illustrated. This study aimed to investigate if GAS exerts the neuroprotective effect through regulating the Notch signaling pathway involved in reactive astrocytes. METHODS: Astrocyte cell lines (TNC1 cells) were cultured in vitro. The hypoxic-ischemic cell model was prepared using the oxygen-glucose deprivation (OGD) method, GAS's pretreatment concentration was 0.34 mM, intervention for 1 hour. Cell counting kit-8 (CCK-8) assay, Transwell migration assay, immunofluorescent staining (double staining), and Western blotting were used to observe the effects of OGD or GAS interference on the function of astrocytes, and the changes of key protein expressions in the Notch signaling pathway were analyzed. RESULTS: GAS had no obvious toxic effect on TNC1 astrocytes under physiological conditions. Following OGD, GAS can not only improve cell viability and migration, but also regulate the production of inflammatory mediators. We also found that OGD significantly increased the expression of key proteins related to the Notch signaling pathway, Notch-1, intracellular Notch receptor domain (NICD), recombining binding protein suppressor of hairless (RBP-JK), transcription factor hairy and enhancer of split-1 (Hes-1) in TNC1 astrocytes, which was significantly inhibited by GAS. In addition, GAS inhibited the OGD-induced expression of TNC1 astrocyte tumor necrosis factor-α (TNF-α) and interleukin 1ß (IL-1ß), and enhanced the expression of nutrient factors, including brain-derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1). The Notch signaling pathway specific inhibitor, N-[N-(3,5-Difluorophenacetyl)-1-alany1]-S-phenyglycine t-butylester (DAPT), could significantly enhance the effect of GAS on TNC1 astrocytes after OGD, such as the inhibition of inflammatory factors and the up-regulation of neurotrophic factors. CONCLUSIONS: GAS exerts dual effects on astrocytes via regulation of the Notch signaling pathway. We found that it could inhibit the pro-inflammatory factors mediated by astrocytes, and also promote the secretion of neurotrophic factors by astrocytes. These results provide a new biological mechanism for the treatment of neuroinflammatory diseases by GAS.
RESUMEN
In response to hypoxic-ischemic brain damage (HIBD), microglia activation and its mediated inflammation contribute to neuronal damage. Inhibition of over-activated microglia is deemed to be a potential therapeutic strategy. Our previous studies showed that gastrodin efficiently depressed the neuroinflammation mediated by activated microglia in HIBD neonatal rats. The underlying mechanisms through which gastrodin acts on activated microglia have not been fully elucidated. This study is designed to determine whether gastrodin would regulate the Notch signaling pathway and Sirtuin3 (Sirt3), which are implicated in regulating microglia activation. The present results showed that gastrodin markedly suppressed the expression of members of Notch signaling pathway (Notch-1, NICD, RBP-JK and Hes-1) in activated microglia both in vivo and in vitro. Conversely, Sirt3 expression was enhanced. In BV-2 microglia treated with a γ-secretase inhibitor of Notch pathway- DAPT, the expression of RBP-JK, Hes-1, and NICD was suppressed in activated microglia. Treatment with DAPT and gastrodin further decreased NICD and Hes-1 expression. Sirt3 expression was also decreased after DAPT treatment. However, Sirt3 expression in activated BV-2 microglia given a combined DAPT and gastrodin treatment was not further increased. In addition, combination of DAPT and Gastrodin cumulatively decreased tumor necrosis factor-α (TNF-α) expression. The results suggest that gastrodin regulates microglia activation via the Notch signaling pathway and Sirt3. More importantly, interference of the Notch signaling pathway inhibited Sirt3 expression, indicating that Sirt3 is a downstream gene of the Notch signaling pathway. It is suggested that Notch and Sirt3 synergistically regulate microglia activation such as in TNF-α production.
Asunto(s)
Alcoholes Bencílicos/farmacología , Glucósidos/farmacología , Hipoxia-Isquemia Encefálica/tratamiento farmacológico , Microglía/efectos de los fármacos , Receptor Notch1/fisiología , Transducción de Señal/efectos de los fármacos , Sirtuinas/fisiología , Animales , Animales Recién Nacidos , Alcoholes Bencílicos/farmacocinética , Arteria Carótida Común , Células Cultivadas , Corteza Cerebral/patología , Cuerpo Calloso/patología , Diaminas/farmacología , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Regulación de la Expresión Génica/efectos de los fármacos , Glucósidos/farmacocinética , Hipoxia-Isquemia Encefálica/metabolismo , Hipoxia-Isquemia Encefálica/patología , Ligadura , Lipopolisacáridos/farmacología , Microglía/metabolismo , Enfermedades Neuroinflamatorias/tratamiento farmacológico , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Receptor Notch1/biosíntesis , Receptor Notch1/genética , Sirtuinas/biosíntesis , Sirtuinas/genética , Tiazoles/farmacología , Factor de Necrosis Tumoral alfa/biosíntesis , Factor de Necrosis Tumoral alfa/genéticaRESUMEN
BACKGROUND AND AIM: Recently, there has been burgeoning interest in the utilization of fully covered self-expandable metal stents (FCSEMSs) for managing main pancreatic duct strictures (MPDS) in chronic pancreatitis (CP). The primary aim was to investigate stricture resolution and recurrence rates of FCSEMS placement in patients with symptomatic CP complicated with MPDS. METHODS: MEDLINE, EMBASE, and ISI Web of Science and Cochrane Library (up to December 2019) were searched to identify eligible studies. A meta-analysis of stricture resolution and recurrence rates was carried out using R. The crude rate of adverse events related to stent therapy was also calculated. RESULTS: Ten studies involving 163 patients were included. The weighted pooled rate of MPDS resolution was 93% (95% confidence interval [95%CI] 84-99%) with substantial heterogeneity (I2 = 63%). Duration of stent placement more than 3 months did not result in a significantly higher resolution rate than that of 3 months or less (93% vs 93%, P = 0.91). The weighted pooled rate of stricture recurrence was 5% (95%CI: 0-12%). The stricture recurrence rate for patients with duration of stent placement more than 3 months (3%; 95%CI: 0-10%) was lower than that in patients with 3 months or less of stent placement (7%; 95%CI: 0-23%), but not significantly (P = 0.45). The overall rate of adverse events related to stent therapy was 34.9%, and spontaneous stent migration occurred in 14.1% of patients. CONCLUSIONS: The use of FCSEMSs appears to be effective and safe in the management of MPDS caused by symptomatic CP.
Asunto(s)
Procedimientos Quirúrgicos del Sistema Digestivo/métodos , Conductos Pancreáticos/fisiología , Conductos Pancreáticos/cirugía , Pancreatitis Crónica/complicaciones , Pancreatitis Crónica/cirugía , Stents Metálicos Autoexpandibles , Constricción Patológica/etiología , Constricción Patológica/cirugía , Humanos , Recurrencia , Reoperación , Seguridad , Stents Metálicos Autoexpandibles/efectos adversos , Resultado del TratamientoRESUMEN
BACKGROUND: Scutellarin, an herbal compound, can effectively suppress the inflammatory response in activated microglia/brain macrophage(AM/BM) in experimentally induced cerebral ischemia; however, the underlying mechanism for this has not been fully clarified. We sought to elucidate if scutellarin would exert its anti-inflammatory effects on AM/BM through the MAPKs pathway. MATERIALS AND METHODS: Western blot and immunofluorescence labeling were used to determine the expression of the MAPKs pathway in AM/BM in rats subjected to middle cerebral artery occlusion (MCAO) also in lipopolysaccharide (LPS)-activated BV-2 microglia in vitro. Furthermore, expression of p-p38 along with that of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta(IL-1ß), and inducible nitric oxide synthase (iNOS) in LPS-activated microglia subjected to pretreatment with p38 inhibitor SB203580, p38 activator sc-201214, scutellarin, or a combination of them was evaluated. FINDINGS: Scutellarin markedly attenuated the expression of p-p38, p-JNK in AM/BM in MCAO rats and in vitro. Conversely, p-ERK1/2 expression level was significantly increased by scutellarin. Meanwhile, scutellarin suppressed the expression of proinflammatory mediators including iNOS, TNF-α, and IL-1ß in AM/BM. More importantly, SB203580 suppressed p-p38 protein expression level in LPS-activated BV-2 microglia that was coupled with decreased expression of proinflammatory mediators (TNF-α, iNOS) in LPS-activated BV-2 microglia. However, p38 activator sc-201214 increased expression of proinflammatory mediators TNF-α, iNOS, and IL-1ß. Interestingly, the decreased expression of both proinflammatory markers by p38 MAPK inhibitor and increased expression of proinflammatory markers by p38 MAPK activator were compatible with that in BV-2-activated microglia pretreated with scutellarin. CONCLUSIONS: The results suggest that scutellarin down-regulates the expression of proinflammatory mediators in AM/BM through suppressing the p-JNK and p-p38 MAPKs. Of note, the anti-inflammatory effect of p38 MAPK inhibitor and scutellarin is comparable. Besides, p38 MAPKs activator reverses the effect of scutellarin. Additionally, scutellarin increases p-ERK1/2 expression that may be neuroprotective.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Apigenina/farmacología , Glucuronatos/farmacología , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Activación de Macrófagos/efectos de los fármacos , Microglía/efectos de los fármacos , Animales , Antiinflamatorios no Esteroideos/uso terapéutico , Apigenina/uso terapéutico , Corteza Cerebral/citología , Corteza Cerebral/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Glucuronatos/uso terapéutico , Imidazoles/farmacología , Infarto de la Arteria Cerebral Media/patología , Mediadores de Inflamación/metabolismo , Masculino , Ratones , Proteínas del Tejido Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Óxido Nítrico Sintasa de Tipo II/biosíntesis , Óxido Nítrico Sintasa de Tipo II/genética , Proteínas Quinasas/biosíntesis , Proteínas Quinasas/genética , Piridinas/farmacología , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Factor de Necrosis Tumoral alfa/biosíntesis , Factor de Necrosis Tumoral alfa/genéticaRESUMEN
Five new organic-inorganic hybrid compounds based on [P2W18O62]6- (abbreviated as {P2W18}) and several types of transition metal complexes (TMCs) have been synthesized and characterized by IR, UV-Vis, XRD, cyclic voltammetry measurements and single crystal X-ray diffraction analysis. [Cu(phen)2][Cu(phen)(H2O)3][Cu(phen)2(H2O)][P2W18O62]·8H2O (1) (phen = 1,10-phenanthroline) is a {P2W18} bi-supported complex of phen, while [Cu(2,2'-bpy)(H2O)2]2[Cu(2,2'-bpy)2][P2W18O62]·3.5H2O (2) (2,2'-bpy = 2,2'-bipyridine) is a 1-D chain structure formed by {P2W18} and copper complexes of 2,2'-bpy. [Ag(2,2'-bpy)2]5[HP2W18O62]·H2O (3), [Ag(2,2'-bpy)(H2O)]2[Ag(2,2'-bpy)]2[Ag2(2,2'-bpy)3][P2W18O62] (4), and [Ag(2,2'-bpy)(H2O)]3[Ag2(2,2'-bpy)3][Ag(2,2'-bpy)][P2W18O62]·H2O (5) are constructed from {P2W18} and silver complexes of 2,2'-bpy. Compounds 4 and 5 are novel dimers of {P2W18} joined by silver complexes, while compound 3 contains two different kinds of silver complexes, forming a novel supramolecular structure. Each of the five compounds is formed by {P2W18} and more than one type of TMC. The formation mechanism of these compounds has been carefully discussed. In addition, we also synthesized two supramolecular structures based on {P2W18} and organic moieties: [H6P2W18O62](phen)5.5 (6) and [H6P2W18O62](phen)3·43H2O (7). The catalytic properties of these compounds were also tested.
RESUMEN
DNA marked-assisted selection of medicinal plants accelerated the breeding and promotion of new cultivars, and guaranteed the healthy development of Chinese medicinal materials industry. The first disease-resistant cultivar of notoginseng, namely "Miaoxiang Kangqi 1", served as the object of study. We evaluated the Kangqi's resistance of seeds, seedlings and root against the pathological bacteria (Fusarum oxysporum) of root rot. Compared to the traditional cultivars, the disease index of notoginseng seeds declined by 52.0% after inoculation for seven days; the death rate of seedlings and disease index of root respectively decreased by 72.1% and 62.4% after inoculation for 25 days. Additionally, the growth inhibition ratio of notoginseng seeds and seedlings declined after inoculation. The seeds, seedlings and roots of "Miaoxiang Kangqi 1" showed significantly resistant to root rot. The evaluation of disease-resistance of Kangqi provided the basis for the popularization of new cultivar and guaranteed the favoring conduct of notoginseng pollution-free cultivation.
Asunto(s)
Resistencia a la Enfermedad/genética , Marcadores Genéticos , Panax notoginseng/genética , Plantas Medicinales/genética , Panax notoginseng/crecimiento & desarrollo , Fitomejoramiento , Enfermedades de las Plantas , Raíces de Plantas , Plantas Medicinales/crecimiento & desarrolloRESUMEN
An unprecedented antimonato-polyoxovanadate (SbPOV) based on both α-[V14Sb8O42]4- and ß-[V14Sb8O42]4- isomers has been hydrothermally synthesized.
RESUMEN
In this paper, a series of CaMoO4 phosphor co-doped rare earth ions were prepared with chemistry co-precipitation method. The concentration of Pr(3+)/Tb(3+) and temperature had obvious influence on the luminescent properties. The crystal structures and spectrum characteristics of the samples were identified with X-ray powder diffraction (XRD) and fluorescence spectrophotometer (PL). According to XRD analysis, the main diffraction peaks of samples are consistent with the standard card (JCPDS 29-0351) of the diffraction peak data. This showed doped rare earth ions did not change matrix lattice structure. The emission spectrum excited by 275 nm exhibit sharp lines peaking at 488, 560, 621 and 560 nm assigned to the (3)P(0)(3)H(4), (3)P(0)(3)H(5)ï¼(1)D(2)(3)H(4) and (3)P(0)(3)F(2) transitions of the Pr(3+) ions. The intensity of fluorescence reached the strongest when the concentration of the doping amount was 3%. The optimum calcination temperatures of CaMoO(4)â¶0.03Pr(3+) and CaMoO(4)â¶0.05Tb(3+) were 800 and 600 â. Furthermore, the intensity of excitation spectra and emission spectra are dependent on the concentration of the doping amount. The emission spectra intensities of CaMoO(4)â¶Pr(3+) phosphors decrease and CaMoO(4)â¶Tb(3+) phosphors firstly increase and then decrease because of concentration quenching effect with increasing Pr(3+) and Tb(3+) concentration. In addition, the luminescence properties of Pr(3+) ion in CaMoO(4)â¶0.03Pr(3+), yTb(3+) system could be evidently improved with co-doping of Tb(3+) ions which was due to the efficient energy transfer process from Tb(3+) to Pr(3+) ions.
RESUMEN
A compound containing the first [V16O39Cl](6-) (V16O39) polyanion has been hydrothermally synthesized and characterized.
RESUMEN
OBJECTIVE: To study on the correlation between chronic asymptomatic HBV carriers (ASC) of yin asthenia constitution and genotypes of HLA-DRB1 and HLA DQA1 alleles. METHODS: Totally 105 ASC were assigned to two groups according to their constitutions, i.e., the yin asthenia group (47 cases) and the non-yin asthenia group (58 cases). The genotypes of HLA-DRB1 and HLA DQA1 alleles were determined using PCR-SSP. RESULTS: The gene frequency of HLA-DRB1 * 09 allele and HLA-DQA1 * 0301 allele (being 12.1% and 19.1%) were obviously lower in the yin asthenia group than in the non-yin asthenia group (being 27.8% and 39.7%, P < 0.05). The gene frequency of HLA-DRB1 * 11 allele and HLA-DQA1 * 0501 allele were obviously higher in the yin asthenia group (being 12.1% and 28.7%) than in the non-yin asthenia group (4.3% and 9.5%), showing statistical difference (P < 0.05, P < 0.01). CONCLUSIONS: HLA-DRB1 * 09 allele and HLA-DQA1 * 0301 allele might be the molecular bases for non-yin asthenia patients with ASC. HLA-DRB1 * 11 allele and HLA-DQA1 * 0501 allele might be the molecular bases for yin asthenia patients with ASC.
Asunto(s)
Portador Sano , Cadenas alfa de HLA-DQ/genética , Cadenas HLA-DRB1/genética , Hepatitis B Crónica/genética , Polimorfismo Genético , Adolescente , Adulto , Constitución y Estatutos , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
OBJECTIVE: To observe p53 expression in liver tissue of patients with chronic hepatitis B and its influencing factors. METHODS: 17 cases HBeAg-negative chronic hepatitis B patients and 31 cases HBeAg-positive chronic hepatitis B patients were divided into 2 groups. RESULTS: (1) HBeAg-negative chronic hepatitis B patients were older, mostly male and HBV DNA lower. These three indicators between two groups patients appeared statistical difference. Serum markers were no statistical difference between two groups patients except Glo. (2) Pathological inflammation and fibrosis Staging were no statistical difference between two groups patients. p53 expression positive rate and p53 expression semi-quantitative scoring in liver tissue were no statistical difference between the two groups. (3) Logistic regression analysis showed that only liver fibrosis staging (S) is a risk factor for p53 expression. Compared with the S0-1, p53 expression increased by 3.9 times the rate of positive in S > or = 2. CONCLUSION: Liver fibrosis staging in patients with chronic hepatitis B is a risk factor for p53 positive expression in liver.
Asunto(s)
Hepatitis B Crónica/genética , Hígado/metabolismo , Proteína p53 Supresora de Tumor/genética , Adulto , Antígenos e de la Hepatitis B/sangre , Hepatitis B Crónica/sangre , Hepatitis B Crónica/metabolismo , Hepatitis B Crónica/patología , Humanos , Hígado/patología , Masculino , Persona de Mediana Edad , Proteína p53 Supresora de Tumor/metabolismoRESUMEN
OBJECTIVE: To investigate the effect of extract of ginkgo biloba leaf (EGb) during the formation of HBV-related hepatocellular carcinoma (HCC). METHODS: 99 HBV transgenic mice were randomly divided into control group, high-dose group, low-dose group. High-dose group and low-dose group were intraperitoneal injected 35mg/(kg x d) and 17.5 mg/(kg x d) of the shuxuening injection. Control group without special treatment. The serological markers and immunohistochemical markers in liver tissue will be done at the first 12 months and 18 months. RESULTS: (1) HBV transgenic mice can be found HCC at the 18 months. The incidence of HCC was lower in high-dose group and low-dose group, there was statistically different among the three groups. (2) The semi-quantitative scoring of liver HBx expression was highest in the control group at the 12 months. The semi-quantitative scoring of liver HBx, p53 and Bcl-2 expression was highest in the control group at the 18 months. They all appeared statistically different among the three groups. (3) Spearman correlation analysis showed that HCC incidence and liver tissue HBx, p53, Bcl-2 expression was a certain degree of positive correlation, r was 0.536, 0.487 and 0.403, P < 0.05. CONCLUSION: EGb can reduced the incidence of the HCC with HBV transgenic mice. The reason may be that the EGb can reduce liver HBx, p53, Bcl-2 protein expression in the HBV transgenic mice.
Asunto(s)
Carcinoma Hepatocelular/prevención & control , Medicamentos Herbarios Chinos/efectos adversos , Ginkgo biloba/química , Hepatitis B/tratamiento farmacológico , Neoplasias Hepáticas/prevención & control , Animales , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/etiología , Carcinoma Hepatocelular/genética , Medicamentos Herbarios Chinos/administración & dosificación , Femenino , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Hepatitis B/complicaciones , Humanos , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/etiología , Neoplasias Hepáticas/genética , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones TransgénicosRESUMEN
OBJECTIVE: To investigate the risk factors related to outcome of chronic severe hepatitis B. METHODS: A total of 336 consecutive patients with chronic severe hepatitis B (CSHB) were analysed retrospectively. According to the outcome, objects were divided into survival group (n = 137) and death group(n = 199), then to observe the differences between them in respect to age, sex, family history, prothrombin activity (PTA), complications including ascites, infection, electrolyte disturbance, upper gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome and the corresponding quantity of complications in each individual, antivirus therapy, artificial liver support system (ALSS) therapy, and alprostadil therapy. Finally, risk factors related to prognosis were selected by stepwise Logistic regression analyse. RESULTS: In univariate analyse, significant differences between the two groups were found related to age, PTA, complications and its quantity (P < 0.01 for all), and antivirus therapy (P < 0.05) rather than sex, family history and treatment of ALSS or alprostadil. Logistic regression revealed that risk factors comprised of PTA and quantity of complications, antivirus therapy was the only protective factor. CONCLUSION: A numbers of factors including age, PTA, complications and its quantity, and antivirus therapy affect the prognosis of CSHB, among which, antivirus therapy can reduce the death rate.
Asunto(s)
Hepatitis B Crónica/diagnóstico , Adulto , Femenino , Humanos , Modelos Logísticos , Masculino , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Resultado del TratamientoRESUMEN
This investigation was made with regard to the influences of ultrasound combined with hematoporphyrin on the activities of antioxidative enzyme in ascites hepatoma 22 (H-22) tumor cells, and to a better understanding of the potential biological mechanism of sonodynamic therapy which involved the damage to cells. Combined with 100 microg/ml hematoporphyrin, high intensity focused ultrasound sonication at a frequency of 1.43 MHz and an intensity level of 2.0 W/cm2 was delivered to H-22 tumor cells for 1 min. The viability of cells was evaluated by typan-blue blue exclusion test. The intracellular reactive oxygen species (ROS) levels were determined by 2',7'-dichlorofluorescein diacetata (DCFH-DA). Enzymatic chemical methods were used to measure the activities of key antioxidative enzymes. The results indicated that the cell damage rate of ultrasound combined with hematoporphyrin was significantly higher than that of the treatment with ultrasound alone, and hematoporphyrin alone had no killing effect on H-22 cells. The level of ROS in cell suspension was significantly increased, and the key antioxidative enzyme activities were obviously decreased after treatment with the combined use of ultrasound and hematoporphyrin. We speculated that the decreased activities of key antioxidative enzymes in cells might be involved in mediating the killing effect on H22 cells in sonodynamic therapy.